Clinical Trials Logo

Mucositis Oral clinical trials

View clinical trials related to Mucositis Oral.

Filter by:

NCT ID: NCT05214495 Completed - Mucositis Oral Clinical Trials

Omega-3 Hydrogel and Prevention of Oral Mucositis

Start date: February 9, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

Oral mucositis (OM) is recognized as one of the most frequent debilitating sequela encountered by head and neck cancer (HNC) patients treated by radiotherapy. The objective of the study is to assess primarily the effect of topical oral Omega-3 hydrogel in prevention of radiation-induced oral mucositis and secondarily, to test the effect of topical oral Omega-3 hydrogel on oral microbiome.

NCT ID: NCT04671862 Recruiting - Clinical trials for Head and Neck Cancer

Photobiomodulation for the Prevention of Radiation Induced Oral Mucositis

Start date: June 1, 2021
Phase: N/A
Study type: Interventional

Radiotherapy for head and neck cancer can cause severe mucositis (ulcers in the mouth) and pain. Photobiomodulation (Light therapy) will be used before and during radiotherapy to try to reduce the occurence and severity of mucositis in patients treated with radiotherapy for head and neck cancer Previous studies in head and neck cancer patients have shown that photobiomodulation (light therapy) can prevent mucositis. There are currently no centers in Canada using this technique in routine practice, but this is recommended in International guidelines and widely used in Europe. The investigators therefore wish to implement this technique in Ottawa under the umbrella of a clinical trial to insure its safety and efficacy in a Canadian context.

NCT ID: NCT04596410 Recruiting - Mucositis Oral Clinical Trials

Photobiomodulation Protocols in the Analgesia of Chemotherapy-induced Oral Mucositis in Children

CURALASE01
Start date: May 3, 2021
Phase: N/A
Study type: Interventional

Chemotherapy-induced oropharyngeal mucositis (OM) negatively impacts the quality of life of adult and pediatric patients by causing pain, dysphagia, dysgeusia and dysphonia. Photobiomodulation (PBM) by low level laser therapy (LLLT), light therapy of low level of red and infrared wavelengths (630-1000 nm) has been recommended since 2014 in patients treated with high-dose chemotherapy for bone marrow transplantation. Available pediatric studies highlighted positive/promising results of PBM with excellent safety and no adverse effects. Nevertheless, a wide variety of application parameters is described in the literature, with no consensus guidelines. Considering the lack of standardized protocol of photobiomodulation in the pediatric population as well as the burden and cost of a daily application, investigators have decided to conduct, for the first time in children of 3 years of age or older, a multicenter, randomized, double-blind, non-inferiority clinical trial to compare two PBM protocols with same PBM parameters, combining red and infrared wavelengths, but with different frequencies of laser application (daily versus every other day), in the treatment of chemotherapy-induced OM of WHO grade 2 or higher.

NCT ID: NCT04303312 Not yet recruiting - Mucositis Oral Clinical Trials

Treatment of Chemotherapy and Radiotherapy Induced Oral Mucositis

Start date: December 2021
Phase: Phase 3
Study type: Interventional

Oral mucositis consequences can range from pain, decreased oral intake, impaired speech and swallowing to adverse events as severe as septicemia, increased hospitalization, and G-tube feeding A wide variety of agents have been tested to prevent OM or reduce its severity.This trial will assess the usefulness of solcoseryl and pumpkin seed oil versus Benzydamine Hydrochloride mouth wash in management of oral mucositis in patients receiving radiotherapy and/or chemotherapy.

NCT ID: NCT04187222 Completed - Mucositis Oral Clinical Trials

Effect of Probiotic Use Bifidobacterium Animalis Subsp. Lactis in Peri-implant Mucositis

Mucosite prob
Start date: July 1, 2018
Phase: Phase 3
Study type: Interventional

Peri-implant disease is an inflammatory process of bacterial etiology that can affect the tissues around the implants and can be classified as peri-implant mucositis or peri-implantitis. The confirmation of the action of probiotics against microorganisms that cause peri-implant diseases can represent a great advance in the treatment of these diseases that affect a large part of the population, and may even reduce or prevent the use of antibiotics, reducing the risk of implant loss and, consequently, greater damage to the oral and systemic health of individuals. The purpose of this study was to evaluate the action of probiotics on the peri-implant health of total edentulous patients using Branemark protocol prosthetic rehabilitations. For this, 38 patients were selected, without systemic alterations and non-smokers. Clinical monitoring was performed at baseline (pre-intervention period) as well as at 12 and 24 weeks after study initiation. The following parameters were evaluated: modified gingival index (MGI), modified plaque index (MPI), probing depth (PD) and probing bleeding (PB). Data were subjected to statistical analysis at a significance level of 5%. There was an increase in sites with IGM 0 in the test group at 12 and 24 weeks. The test group presented more sites with IGM 0 than the control. IPM 0 sites increased in the control group at 12 and 24 weeks in the control group. PD decreases in a test and control group. Finally, the test group had lower PB rates. Thus, the probiotic used demonstrated ability to contribute to the improvement of peri-implant health of the patients analyzed.

NCT ID: NCT04080622 Not yet recruiting - Clinical trials for Stem Cell Transplant Complications

Evaluate the Efficacy of Selenium for the Prevention of Chemotherapy-induced Mucositis During Autologous Stem Cell Transplantation.

AutoSelenium
Start date: October 2019
Phase: Phase 3
Study type: Interventional

Chemotherapy-induced mucositis is an important complication after autologous stem cell transplantation. It is mainly responsible for pain and dysphagia requiring opioids and artificial nutrition. It can also induce infectious complications. A few medication has demonstrated efficacy in this setting. It has been suggested that selenium can reduce the intensity of mucositis due to its antioxydant activity. The investigators therefore perform a randomized study to confirm this preliminary data.

NCT ID: NCT03983369 Recruiting - Mucositis Oral Clinical Trials

Low-level Laser Therapy in the Prevention of Chemotherapy-induced Mucositis in Children and Young Adults

MUCILA
Start date: August 29, 2018
Phase: Phase 3
Study type: Interventional

To assess the efficacy of preventive Low-Level Laser Therapy (LLLT) for reducing the incidence of WHO's grade 3-4 oral mucositis in children and young adults receiving chemotherapy regimens associated with a high rate of mucositis: conventional chemotherapy or High Dose Chemotherapy (HDC) conditioning regimens with Hematological Stem Cell Transplantation (HSCT).

NCT ID: NCT03577535 Completed - Mucositis Oral Clinical Trials

Evaluation of ONCOXIN® in Oral Mucositis, Appetite and Body Mass in Cancer Patients.

Start date: November 1, 2017
Phase: Phase 2
Study type: Interventional

Oral mucositis is one of the most spread side effects of anticancer therapy. It is associated with both chemo- and radiotherapy, decreases QoL, relative dose intensity and leads to nutritive deficiency. Oral mucositis causes secondary infections, increased hospital stay, whereas pain syndrome results in an emotional distress, anorexia and disables natural feeding.

NCT ID: NCT03461354 Active, not recruiting - Clinical trials for Head and Neck Cancer

MucoLox Formulation to Mitigate Mucositis Symptoms in Head/Neck Cancer

Start date: April 9, 2018
Phase: N/A
Study type: Interventional

This study will examine if the administration of prophylactic MucoLox formulation versus sodium bicarbonate mouthwash in subjects with head/neck cancer receiving radiation ± chemotherapy will result in significantly fewer subjects experiencing severe mucositis.

NCT ID: NCT03416582 Completed - Lung Cancer Clinical Trials

Feasibility Study of a Nurse Intervention to Impact Mucositis Severity and Prevent Dehydration

Start date: November 29, 2018
Phase: N/A
Study type: Interventional

This is a descriptive mixed method pilot study to determine the feasibility of a tailored nurse-delivered telephone intervention designed to impact mucositis symptom severity and prevent dehydration in lung and head/neck cancer patients undergoing chemoradiation, therefore reducing overall symptom severity and improving quality of life. Secondary purposes for this study are to investigate if the nursing intervention can decrease lung and head/neck cancer patients' unscheduled medical visits between chemoradiation treatments.